Fiduciary Trust’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

Fiduciary Trust’s Portfolio LOGC Stock Details LOGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-47,998	Closed	-$13K	–	645
2022 Q3	$13K	Hold	47,998	–	–	﹤0.01%	609
2022 Q2	$17K	Hold	47,998	–	–	﹤0.01%	626
2022 Q1	$33K	Buy	47,998 +10,000	+26%	+$11K	﹤0.01%	660
2021 Q4	$88K	Hold	37,998	–	–	﹤0.01%	647
2021 Q3	$174K	Hold	37,998	–	–	﹤0.01%	633
2021 Q2	$169K	Hold	37,998	–	–	﹤0.01%	624
2021 Q1	$277K	Hold	37,998	–	–	0.01%	543
2020 Q4	$290K	Hold	37,998	–	–	0.01%	508
2020 Q3	$345K	Hold	37,998	–	–	0.01%	451
2020 Q2	$321K	Hold	37,998	–	–	0.01%	443
2020 Q1	$188K	Buy	37,998 +6,998	+23%	+$54.4K	0.01%	476
2019 Q4	$223K	Buy	+31,000	New	+$280K	0.01%	488

Fiduciary Trust's LOGC Position: Q4 2022 in Review

Fiduciary Trust sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q4 2022, closing a stake of 47,998 shares — an estimated $13K sold.

Fiduciary Trust first reported a position in LOGC in Q4 2019 and held it in 12 quarters. The position peaked at $345K in Q3 2020. 0 funds tracked by Wall St. Rank hold LOGC as of Q4 2022.

Fiduciary Trust reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Fiduciary Trust sold 47,998 LogicBio Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $13K.
Fiduciary Trust first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q4 2019 and held it in 12 quarters.
Fiduciary Trust's LogicBio Therapeutics, Inc. Common Stock position peaked at $345K in Q3 2020.
0 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Fiduciary Trust's 13F filing for Q4 2022, filed 14 Feb 2023.